Search results
Results from the WOW.Com Content Network
Exact Sciences Corp. is an American molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer ; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer .
On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for ...
Biomatrica, Inc. is a United States-based biotechnology company, and subsidiary of Exact Sciences Corporation, that develops chemicals for ambient temperature preservation of biological materials for the purpose of expanding the availability and accuracy of medical diagnostics and research.
Exact Sciences said it will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium scheduled next month.
Genomic Health, Inc. was founded in 2000 by Randy Scott, who had previously founded and been CEO at Incyte. [4] He formed the company after a close friend was diagnosed with cancer and had the idea for treatment based on the specific genome of their tumor.
The company said it plans to complete submission of its marketing application for the new test to the U.S. Food and Drug Administration (FDA) by the end of this year. The company reported $1.43 ...
Exact Sciences (NASDAQ: EXAS) Q3 2024 Earnings Call Nov 05, 2024, 5:00 p.m. ET. Contents: ... And adding on to that new products with our launch of MRD occurring next year too in the first half.
EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year